Unity Biotechnology, Inc. (UBX) SEC Filing 10-K Annual Report for the fiscal year ending Saturday, December 31, 2022

Cash provided by financing activities of $63.9 million for the year ended December 31, 2020 was related to $37.3 million in proceeds from the sale of common stock through our ATM Offering Program, net of issuance costs, $24.2 million in proceeds from long-term debt, net of issuance costs, $1.5 million in proceeds from issuance of common stock upon exercise of stock options, net of repurchases, $0.6 million in proceeds from the issuance of common stock under the 2018 Employee Stock Purchase Plan, and $0.4 million in proceeds from the repayment of promissory notes from an employee.

Cash provided by financing activities of $20.8 million for the year ended December 31, 2021 was related to $10.4 million in proceeds from the sale of common stock through our ATM Offering Program, net of issuance costs, $8.2 million in proceeds from issuance of common stock to Lincoln Park Capital Fund, net of issuance costs, $1.8 million in proceeds from issuance of common stock upon exercise of stock options, net of repurchases, $0.3 million in proceeds from the issuance of common stock under the 2018 Employee Stock Purchase Plan and $0.2 million in proceeds from the repayment of employee promissory note, partially offset by $0.1 million current portion of long-term debt arrangement.